Arecor, the biopharmaceutical company advancing today’s therapies to enable healthier lives, has announced that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organisation funding type 1 diabetes (T1D) research. Under this collaboration, Arecor and JDRF will contribute matching funds to develop a stable, liquid co-formulation of pramlintide and insulin … Continued
Normal initial fees of 3-5% waived until end of November Award-winning Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) specialist, Calculus Capital, is waiving initial fees on its VCT until the end of November. The VCT is aiming to deliver an annual tax-free dividend of 4.5%, as well as capital growth. Earlier this year … Continued
Dosing complete in Phase 1 clinical trial of ultra-rapid acting insulin product candidate AT247 for Diabetes. HEADLINE DATA READOUT EXPECTED Q4 2019 Calculus Capital portfolio company, Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announced completion of dosing and all patient visits in its Phase I clinical trial … Continued
Calculus Capital are delighted to be finalists in three categories at the upcoming Tax Efficiency Awards 2019/20. Best Generalist – EIS Best Generalist – VCT Exit of the Year The awards are designed to recognise the most successful and forward-thinking providers in the areas of VCTs, EIS and BPR/IHT. Winners will be announced on Friday … Continued
Genedrive plc has received approval from the NHS Health Research Authority to start testing its Antibiotic Induced Hearing (AIHL) test in hospital trials. The AIHL test will be trialled in 1,000 patients from two large UK intensive care units in a study (PALOH) scheduled to start in November that will run for six months. This … Continued
Calculus VCT is open for subscription – invest in the brightest, growing UK businesses Calculus Capital has launched a £10 million fundraising for the Calculus VCT, offering a target annual dividend of 4.5% of NAV and capital growth. The proceeds from the fundraising will be used to invest in new companies and to provide additional … Continued
Money Dashboard were victorious at the Scottish Financial Technology Awards on 25 September, picking up Fintech of the Year & Best Fintech Collaboration. Congratulations to all at Money Dashboard for these well deserved achievements at Scotland’s only Awards decicated to excellence in Financial Services Technology & Fintech.
Platform to potentially increase the potency of any therapeutic monoclonal antibody Scancell, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has signed its first collaboration and non-exclusive research agreement with a leading antibody technology company to assess its pipeline of monoclonal antibodies (mAbs) targeting tumourassociated glycans (TaGs) … Continued
As reported in the Scotsman: Money Dashboard, the personal finance app based in Edinburgh, has raised more than £4.6 million to triple headcount and make its app available “to the masses”. The fintech has closed what it describes as this year’s biggest fintech raise on crowdfunding platform Crowdcube, receiving pledges from 3,300 investors as it … Continued
Scottish biotech company, and the market leader in gene therapy control technologies, Synpromics, has been bought by AskBio, the American pioneer in gene therapeutics. EIS and VCT fund manager Calculus Capital, which first invested in Synpromics in 2015 and invested £5.6m into the company in total, will receive a return on investment that significantly exceeds … Continued